1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Abattis Bioceuticals Corp.
  6. News
  7. Summary
    ATT   CA00258G1037

ABATTIS BIOCEUTICALS CORP.

(ATT)
End-of-day quote CANADIAN NATIONAL STOCK EXCHANGE  -  2019-02-03
0.0800 CAD   -.--%
2020Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 30, 2019
CI
2019Abattis Bioceuticals Corp. Announces Board Changes
CI
2019Abattis Bioceuticals Corp. Reports Earnings Results for the Third Quarter Ended June 30, 2019
CI
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Abattis Announces Resignation of Directors

03/09/2019 | 11:05am EDT

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2019) - Abattis Bioceuticals Corp (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") announces that, effective February 20, 2019 and March 6, 2019, both Wolfgang Richter and James Irving have respectively resigned as directors of the Company.

The Company thanks both Mr. Richter and Mr. Irving for their service and wishes each all the best in their future endeavors.

About Abattis Bioceuticals Corp.

Abattis is positioned to be a leader in the cannabis industry as a fully integrated medicinal cannabis company. The Company's flagship cultivation asset is located on beautiful British Columbia's Gabriola Island, where the Company plans to grow medical-grade cannabis and select craft strains of infamous "B.C. Bud".

Abattis has also continued to organically grow its products divisions. From its Abattis-branded vaporizer line, to the recent launch of its first proprietary cannabinoid therapeutic formulated for pain, COMFORT™. Abattis also continues to service the cultivation industry through its preferred service agreements with Northern Vine Canada Inc. and Dicentra Inc., one of Canada's largest regulatory advisory firms.

To further its reach into the cannabis space, Abattis has made several strategic investments into cutting-edge research performed in partnership with the University of British Columbia and Mitacs, to research and develop nanoemulsified cannabinoid-rich hemp oil. As well as investments into XLABS Therapeutics (ONT) Inc., building one of Canada's largest cannabinoid manufacturing.

ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,

"Rob Abenante"

Robert Abenante, President & CEO

For more information, please visit the Company's website at: www.abattis.com

For inquiries please contact 1 (808) 650-3007 or at investors@abattis.com. Abattis' investor relations are managed by Canada One Communications Inc.

About Canada One Communications Inc.

Canada One Communications Inc. ("Canada One") is a full-service Investor Relations and Marketing company that focuses on both private and public sectors within the Canadian markets. Canada One offers timely responses to all investor inquiries over several mediums and effective, thorough market awareness programs that are specifically designed to maximize exposure and bring value to shareholders. Canada One's dedicated and experienced team strives to promote client information to the public and educate potential investors on the various developments of its clients. From basic phone-call and email investor correspondence, to full-scale comprehensive marketing packages which includes industry analysis, website development, corporate videos and other marketing programs, Canada One provides a full suite of services that are fully compliant with Canadian securities regulations. Canada One is driven by an uncompromising dedication to provide publicly listed and private companies with across-the-board investor relations and marketing solutions, directly translating these services into organic growth and increased market value of its valued clients.

The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/43317


© Newsfilecorp 2019
All news about ABATTIS BIOCEUTICALS CORP.
2020Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 3..
CI
2019Abattis Bioceuticals Corp. Announces Board Changes
CI
2019Abattis Bioceuticals Corp. Reports Earnings Results for the Third Quarter Ended June 30..
CI
2019Abattis Bioceuticals Corp.'s Equity Buyback announced on August 7, 2018, has expired.
CI
2019Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 3..
CI
2019ABATTIS BIOCEUTICALS CORP. (OTCPK : ATTB.F) completed the acquisition of Pro Natura BV fro..
CI
2019ABATTIS BIOCEUTICALS : Announces Acquisition of European Nutraceutical Company and Provide..
PR
2019Abattis Bioceuticals Corp. Announces Management Changes
CI
2019ABATTIS BIOCEUTICALS CORP. (OTCPK : ATTB.F) agreed to acquire Pro Natura BV from The Catal..
CI
2019Abattis Bioceuticals Corp. Announces Resignations in Board
CI
More news
Chart ABATTIS BIOCEUTICALS CORP.
Duration : Period :
Abattis Bioceuticals Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Francesco Paolini Chief Financial Officer & Director
Patrick Mitchell Chief Operating Officer & Director
Cedric Wilson Director
Jonathan Danieli Investor Relations Contact
Nicole Breitinger Secretary
Sector and Competitors